Monte Rosa Therapeutics
- Market cap
- 867.64M
- P/E (TTM)i
- -5.81
- P/Bi
- 1.78
- EPSi
- -0.46
- Div yieldi
- 0.00%
- 52W posi
- 7%
Anonymous reader poll. Unscientific, not investment advice.
Monte Rosa Therapeutics shares were changing hands at 10.17, up 3.04% on the day. The company carries a market value of roughly 867.64M, the #3350 most valuable US-listed company we track. Trading at a P/E of -5.81, the stock is 316% below its own five-year norm of 2.69. Wall Street's 7-analyst consensus lands on Buy, with a price target averaging 28.17 (+177% from here). Against a 52-week band of 8.94-25.77, the shares are currently 7% of the way up.
✦ StockVane Quant Insights how this is computed
- Not yet in the StockVane Momentum strategy's universe - this name needs price history back to 2021 for a reliable signal and doesn't have it yet (most often because it IPO'd or was spun off more recently). This grade is a preliminary blend of valuation, momentum and analyst data, not a Momentum buy/sell call.
- Valuation sits at the 52% percentile of its own 5-year range.
- Price momentum averages -10.3% across the trailing 3-month/1-year windows.
- Analyst consensus across 7 analysts is Buy.
- Recent price momentum is -10.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 22.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 9.87
- Open
- 9.84
- Day range
- 9.68 - 10.75
- Avg price
- 10.28
- Volume
- 2.08M
- Turnover
- 21.39M
- Turnover ratei
- 3.82%
- Volume ratioi
- 1.18
- Amplitudei
- 10.84%
- 52-week rangei
- 8.94 - 25.77
Valuation
- P/Ei
- -22.11
- P/E (TTM)i
- -5.81
- P/Bi
- 1.78
- EPSi
- -0.46
- Book value / shi
- 5.71
- Net profit
- -39.24M
- Net assets
- 487.31M
Share structure
- Market cap
- 867.64M
- Float capi
- 554.02M
- Shares out
- 85.31M
- Float sharesi
- 54.48M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-06-24
60.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-4.63M net over the window
Short interest
- Shares short
- 19.27M
- % of floati
- 22.58%
- Days to coveri
- 17.08
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics last traded at 10.17. The quote on this page refreshes every few seconds while US markets are open.
What is Monte Rosa Therapeutics's market cap?
About 867.64M.
What is the P/E ratio of Monte Rosa Therapeutics?
The trailing twelve-month P/E is -5.81, below its own 5-year average of 2.69 — toward the bottom of its historical range (12.05% percentile). See the Valuation tab for the full history.
Does Monte Rosa Therapeutics pay a dividend?
Monte Rosa Therapeutics does not currently pay a regular dividend.
Is Monte Rosa Therapeutics a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 28.17, which implies 177.0% upside from the current price. This is not investment advice.
Quote time 2026-10-08 07:41:47 · For reference only, not investment advice and not tailored to your situation.